Michael Akers

Vacuum Vial Infusion System

Application

#4573967 Mar 4, 1986

Filed

Dec 6, 1983

Inventor

William W. Hargrove (Indianapolis, IN) · Dale C. Harris (Fairland, IN) · Michael J. Akers (Greenwood, IN) · Charles R. Sperry (Westport, CT)

Appl. No.

6/558060

Assignee

Eli Lilly and Company (Indianapolis, IN)

International Classification

A61W 500

U.S. Classification

604 56

Abstract

An apparatus for connecting a vial into the delivery tube of an intravenous administration set, the set including a container of fluid connected to one end of a delivery tube with the other end of the delivery tube adapted for insertion into the patient. The apparatus includes a penetrating spike penetrating an end of the vial which provides two pathways into the interior of the vial with two sections of the delivery tube connected to the two pathways of the penetrating spike. The apparatus also includes a frame for maintaining the two sections of the delivery tube adjacent to each other and clamp for releasably closing the adjacent sections of the delivery tube to temporarily prevent flow of fluid through the penetrating spike.

Liquid Insulin Compositions And Methods Of Making The Same

Application

#2016003 Feb 4, 2016

Filed

May 5, 2015

Inventor

David John STOKELL (Indianapolis, IN) · Michael Patrick AKERS (Indianapolis, IN)

Appl. No.

14/704838

Assignee

STELIS BIOPHARMA PVT. LTD. (Bangalore)

International Classification

A61K 38/28, C07K 14/62

Abstract

Disclosed herein are novel and improved preparations and methods for manufacturing substantially liquid preparations of recombinant human insulin API. The purified recombinant human insulin Active Pharamaceutical Ingredient (API) preparations are substantially free of by-products associated with the lyophilization and/or crystallization. The methods for manufacturing the substantially liquid recombinant human insulin API preparations are provided with optional steps for subjecting the recombinant insulin preparation to lyophilization and/or crystallization. Enhanced yield of recombinant insulin of greater purity are thereby provided according to the present invention. Highly purified formulations of recombinant human insulin of the API insulin preparations disclosed herein are also provided. Stably transformed cell banks (WCB) capable of expressing the recombinant human insulin are also provided

Aspart Proinsulin Compositions And Methods Of Producing Aspart Insulin Analogs Therefrom

Application

#2012021 Aug 23, 2012

Filed

Feb 23, 2011

Inventor

Ronald E. Zimmerman (Greenwood, IN) · David John Stokell (Indianapolis, IN) · Michael Patrick Akers (Indianapolis, IN)

Appl. No.

13/032775

Assignee

Elona Biotechnologies (Greenwood, IN)

International Classification

C07K 14/62, C12N 1/21, C12P 21/02, C12N 15/63

U.S. Classification

530303, 4353201, 43525233, 435 694

Abstract

Aspart modified proinsulin sequences that have a modified C-peptide amino acid and/or nucleic acid modification for producing aspart insulin analogs are provided. Highly efficient processes for preparing the aspart insulin analogs and improved preparations containing the aspart insulin analogs prepared according to the methods described herein are also provided.

Controlled Release Infusion System

Application

#4534758 Aug 13, 1985

Filed

Jul 15, 1983

Inventor

Michael J. Akers (Greenwood, IN) · William W. Hargrove (Indianapolis, IN) · Dale C. Harris (Fairland, IN) · Charles R. Sperry (Westport, CT)

Appl. No.

6/514268

Assignee

Eli Lilly & Company (Indianapolis, IN)

International Classification

A61M 514

U.S. Classification

604 85

Abstract

Valved adaptors are disclosed permitting the introduction of a drug-containing vial in the delivery tube of an I. V. administration set. The adaptors have a three position operation characterized by a bypass mode, a dilution mode, and a delivery mode, the adaptors being manually changed from mode to mode. The disclosed adaptors include gravity operated valves, reciprocating spool valves, and rotating spool valves, each including a spike to penetrate the stopper of a vial and a vent to permit air to escape the vial as liquid is introduced to dilute the vial contents.

Aspart Proinsulin Compositions And Methods Of Producing Aspart Insulin Analogs

Application

#2016002 Jan 28, 2016

Filed

May 29, 2015

Inventor

David J. STOKELL (Indianapolis, IN) · Michael P. AKERS (Indianapolis, IN)

Appl. No.

14/725039

Assignee

STELIS BIOPHARMA PRIVATE LIMITED (BANGALORE)

International Classification

C07K 14/62

Abstract

Aspart modified proinsulin sequences that have a modified C-peptide amino acid and/or nucleic acid modification for producing aspart insulin analogs are provided. Highly efficient processes for preparing the aspart insulin analogs and improved preparations containing the aspart insulin analogs prepared according to the methods described herein are also provided.

Lis-Pro Proinsulin Compositions And Methods Of Producing Lis-Pro Insulin Analogs Therefrom

Application

#2013021 Aug 15, 2013

Filed

Apr 17, 2013

Inventor

David J. Stokell (Indianapolis, IN) · Michael P. Akers (Indianapolis, IN)

Appl. No.

13/864955

Assignee

HORIZON BANK NA (FRANKLIN, IN)

International Classification

C07K 14/62

U.S. Classification

514 59, 4353201, 43525233, 435 691, 435 681

Abstract

Lis-Pro modified proinsulin sequences that have a modified C-peptide amino acid and/or nucleic acid modification are presented. Methods for producing Lis-Pro insulin analogs are also disclosed. Highly efficient processes for preparing the Lis-Pro insulin analogs and improved preparations containing the Lis-Pro insulin analogs prepared according to the methods described herein are also provided.